home *** CD-ROM | disk | FTP | other *** search
- BUSINESS, Page 54Business NotesPHARMACEUTICALSPrescription For a Merger
-
-
- Tums, meet Tagamet. The race to create global pharmaceutical
- companies inspired a transatlantic merger last week. London's
- Beecham Group, maker of Tums antacid, and Philadelphia's SmithKline
- Beckman, developer of the anti-ulcer drug Tagamet, said they will
- form a company with more than $6.7 billion in total sales. The
- merged corporation, to be renamed SmithKline Beecham, will rank No.
- 2 in the pharmaceutical world to New Jersey-based Merck.
-
- The move comes none too soon for SmithKline, which has suffered
- from declining Tagamet sales as the once revolutionary drug faces
- increased competition. Industry experts see the two companies as
- a good match. Beecham, which also makes Brylcreem, has built strong
- European markets, while SmithKline prevails in North America and
- Japan.